Roche Venture Fund has reinvested in Horizon Discovery's third round of funding.
UK-based personal medicine company Horizon Discovery has raised £6.25m ($9.9m) in its series C round and revealed Switzerland-based pharmaceuticals company Roche as its corporate venturing investor.
Roche Venture Fund has reinvested in Horizon’s third round of funding, which was led by venture capital firm DFJ Esprit as a new investor and included angel investors David Evans, chairman of AIM-quoted Immunodiagnostic Systems, and Jonathan Milner, chief executive of antibody supplier Abcam that has had one of Europe’s most successful flotations in…